MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arbutus Biopharma Corp

Fechado

4.18 -3.02

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.16

Máximo

4.28

Indicadores-chave

By Trading Economics

Rendimento

27M

2.5M

Vendas

9M

11M

Margem de lucro

23.494

Funcionários

44

EBITDA

27M

2.6M

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

215M

855M

Abertura anterior

7.2

Fecho anterior

4.18

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Arbutus Biopharma Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2025, 16:58 UTC

Ganhos

BMW Trims 2025 View, Citing Weaker Performance in China

7 de out. de 2025, 23:43 UTC

Conversa de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 de out. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 de out. de 2025, 23:19 UTC

Conversa de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 22:50 UTC

Conversa de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 de out. de 2025, 22:40 UTC

Conversa de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

7 de out. de 2025, 21:56 UTC

Conversa de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 20:44 UTC

Ações em Alta

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 de out. de 2025, 19:42 UTC

Conversa de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 de out. de 2025, 19:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 de out. de 2025, 19:07 UTC

Conversa de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 de out. de 2025, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de out. de 2025, 16:20 UTC

Conversa de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 de out. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 15:37 UTC

Conversa de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 de out. de 2025, 15:33 UTC

Conversa de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 de out. de 2025, 15:25 UTC

Conversa de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 de out. de 2025, 15:15 UTC

Conversa de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 de out. de 2025, 15:04 UTC

Conversa de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de out. de 2025, 14:56 UTC

Conversa de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 de out. de 2025, 14:52 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Arbutus Biopharma Corp Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

3.255 / 3.365Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
help-icon Live chat